February 27, 2023
Pfizer Japan said on February 24 that it has filed a new drug application in Japan for its PARP inhibitor talazoparib for the treatment of “BRCA-mutated, HER2-negative, inoperable or recurrent breast cancer” and “castration-resistant prostate cancer (CRPC).” For breast cancer,...read more